| Expression pattern: |
UP |
| Associated gene: |
AGO2, CXCL1 |
| Associated microRNA: |
miR-203a-3p.1, miR-217, miR-222 |
| Biological function: |
promotes CRC cell proliferation and invasion; promotes immune evasion (increases MDSCs and decreases CD8+ T cells); promotes anti-PD-1 resistance; promotes tumor growth in vivo |
| Molecular mechanism: |
acts as a ceRNA sponging miR-203a-3p.1 to regulate CXCL1, thereby modulating tumor immune microenvironment and PD-1 antibody responsiveness |
| Biological pathway or process: |
proliferation (promotes); invasion (promotes); immune regulation (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Flow Cytometry（Non-apoptosis/cycle）; Survival Analysis |
| Clinical significance: |
High circNCOA3 level was correlated with poor OS and PFS of CRC patients who received PD-1 antibody treatment; potential biomarker to predict efficacy and prognosis in anti-PD-1-treated CRC |
| Description: |
circNCOA3 (has_circ_0060627) is up-regulated in CRC, particularly in anti-PD-1-resistant patients. It promotes proliferation and invasion and drives immune evasion by altering tumor-infiltrating immune cells, reducing sensitivity to PD-1 blockade. Mechanistically, it acts as a ceRNA for miR-203a-3p.1 to increase CXCL1, and high circNCOA3 is associated with poor OS/PFS in PD-1-treated CRC patients. |
| Confidence score: |
0.8851 |